AR015893A1 - STRUCTURAL FRAGMENT DERIVED FROM OXYETHYLENE, DERIVATIVES BETA-AMINO AND BETA-AZIDO OF CARBONIC ACID THAT UNDERSTAND IT, ITS USE TO TREAT ASANTAGONIST DISEASES OF ENDOTHELINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS FOR ORGANIZATIONAL COMPREHENSION, WHICH - Google Patents

STRUCTURAL FRAGMENT DERIVED FROM OXYETHYLENE, DERIVATIVES BETA-AMINO AND BETA-AZIDO OF CARBONIC ACID THAT UNDERSTAND IT, ITS USE TO TREAT ASANTAGONIST DISEASES OF ENDOTHELINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS FOR ORGANIZATIONAL COMPREHENSION, WHICH

Info

Publication number
AR015893A1
AR015893A1 ARP980102873A ARP980102873A AR015893A1 AR 015893 A1 AR015893 A1 AR 015893A1 AR P980102873 A ARP980102873 A AR P980102873A AR P980102873 A ARP980102873 A AR P980102873A AR 015893 A1 AR015893 A1 AR 015893A1
Authority
AR
Argentina
Prior art keywords
substituted
phenyl
beta
nitrogen
alkyl
Prior art date
Application number
ARP980102873A
Other languages
Spanish (es)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR015893A1 publication Critical patent/AR015893A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un fragmento estructural de la formula I y derivados beta-amino y beta-azido de ácido carbonico que lo comprenden de la formula II en donde R1 representatetrazol o a un grupo -C:O-R en el que R tiene el siguiente significado: a)un residuo OR4, dondeR4 significa. hidrogeno, el cation de un metal alcalino, elcation de un metal alcalinotérreo, un ion amonio orgánico fisiologicamente compatible tal como C1-4-alquilamonio terciario o el ion amonio, C3-8-cicloalquilo,C1-8-alquilo, que puede sersusti tuido CH2-fenilo que puede ser sustituido, un grupo C3-6-alquenilo o C3-6 alquinilo, que puede ser sustituido, fenilo, quepuede ser sustituido, b) un heteroaromático de 5 eslabones ligado por medio de un átomo de nitrogeno, c)es un grupo IIIen el qu e K toma los valores 0, 1 y 2,p los valores 1, 2, 3 y 4 R5 representa C1-4-alquilo, C3-8-cicloalquilo, C3-8-alquenilo, C3-8-alquinilo o fenilo, que puede ser sustituido, d)es un residuo IVen el que R6 significa: C1-4-alquilo,C3-8-alquenilo, C3-8-alq uinilo, C3-8-cicloalquilo, donde estos residuos pueden tener un residuo C1-4-alcoxi,C1-4-alquiltio y/o un residuo de fenilo, C1-4-haloalquilo o fenilo, que puede ser sustituido A NR7R8 o azido, W y Z (que pueden ser igualeso diferentes):nitrogeno o metino con la condicion de que si W y Z = metino, entonces Q = nitrogeno, X nitrogeno o CR9, Y nitrogeno o CR10, Q nitrogeno o CR11, con lacondicion que si Q = nitrogeno, entonces X = CR9 y Y = CR10, R2 y R3 (que pueden seriguales o diferentes) son: fenilo o naftilo, que pueden ser sustituidosfenilo o naftilo, que pueden estar unidos en posicion orto por una union directa a un grupo metileno, etileno o etenileno, a un átomo de oxígeno o azufre o aun grupo SO2, NH- oN-alquilo, C5-6-cicloalquilo , donde estos residuos pueden ser sustituidos, R7 hidrogeno, C1-8-alquilo, C3-8-alquenilo o C3-8-alquinilo,C1-5-alquilcarbonilo, que pueden estar sustituidos, fenilo o naftilo, que pueden ser sustituidoC3-8-cicloalquilo, que pueden ser sustituido, o R7 está unidocon R8 por medio de 4 o 5 grupos CH2 para dar un anillo de 5 o 6 miembros, y R8 es hidrogeno, C2-4-alquilo, o R8 está unido con R7, por medio de 4 o 5 gruposA structural fragment of formula I and beta-amino and beta-azido derivatives of carbonic acid comprising it of formula II wherein R 1 represents tetrazol or a group -C: OR in which R has the following meaning: a) a residue OR4, where R4 means. hydrogen, the cation of an alkali metal, elcation of an alkaline earth metal, a physiologically compatible organic ammonium ion such as C1-4-tertiary alkylammonium or the ammonium ion, C3-8-cycloalkyl, C1-8-alkyl, which can be substituted CH2-phenyl which can be substituted, a C3-6-alkenyl or C3-6 alkynyl group, which can be substituted, phenyl, which can be substituted, b) a 5-link heteroaromatic linked by means of a nitrogen atom, c) is a group III in which K takes the values 0, 1 and 2, p the values 1, 2, 3 and 4 R5 represents C1-4-alkyl, C3-8-cycloalkyl, C3-8-alkenyl, C3-8 -alkynyl or phenyl, which can be substituted, d) is an IV residue in which R6 means: C1-4-alkyl, C3-8-alkenyl, C3-8-alkynyl, C3-8-cycloalkyl, where these residues can having a C1-4-alkoxy, C1-4-alkylthio residue and / or a phenyl, C1-4-haloalkyl or phenyl residue, which can be substituted A NR7R8 or azido, W and Z (which may be equally different): nitrogen or methine with the condition that if W and Z = methine, then Q = nitrogen, X nitrogen or CR9, Y nitrogen or CR10, Q nitrogen or CR11, with the condition that if Q = nitrogen, then X = CR9 and Y = CR10, R2 and R3 (which can be serigual or different) are: phenyl or naphthyl, which can be substituted phenyl or naphthyl, which can be linked in ortho position by a direct union to a methylene, ethylene or ethenylene group, to an oxygen or sulfur atom or even group SO2, NH- or N-alkyl, C5-6-cycloalkyl, where these residues can be substituted, R7 hydrogen, C1-8-alkyl, C3-8-alkenyl or C3-8-alkynyl, C1-5-alkylcarbonyl, which they can be substituted, phenyl or naphthyl, which can be substituted C3-8-cycloalkyl, which can be substituted, or R7 is linked with R8 by means of 4 or 5 CH2 groups to give a 5 or 6 member ring, and R8 is hydrogen, C2-4-alkyl, or R8 is linked to R7, by means of 4 or 5 groups

ARP980102873A 1997-06-19 1998-06-17 STRUCTURAL FRAGMENT DERIVED FROM OXYETHYLENE, DERIVATIVES BETA-AMINO AND BETA-AZIDO OF CARBONIC ACID THAT UNDERSTAND IT, ITS USE TO TREAT ASANTAGONIST DISEASES OF ENDOTHELINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS FOR ORGANIZATIONAL COMPREHENSION, WHICH AR015893A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19726146A DE19726146A1 (en) 1997-06-19 1997-06-19 New ß-amino and ß-azidopcarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
AR015893A1 true AR015893A1 (en) 2001-05-30

Family

ID=7833081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102873A AR015893A1 (en) 1997-06-19 1998-06-17 STRUCTURAL FRAGMENT DERIVED FROM OXYETHYLENE, DERIVATIVES BETA-AMINO AND BETA-AZIDO OF CARBONIC ACID THAT UNDERSTAND IT, ITS USE TO TREAT ASANTAGONIST DISEASES OF ENDOTHELINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS FOR ORGANIZATIONAL COMPREHENSION, WHICH

Country Status (22)

Country Link
EP (1) EP0994861A1 (en)
JP (1) JP2002504130A (en)
KR (1) KR20010013981A (en)
CN (1) CN1261352A (en)
AR (1) AR015893A1 (en)
AU (1) AU8213398A (en)
BG (1) BG104022A (en)
BR (1) BR9810182A (en)
CA (1) CA2294050A1 (en)
CO (1) CO4950605A1 (en)
DE (1) DE19726146A1 (en)
HR (1) HRP980331A2 (en)
HU (1) HUP0002714A3 (en)
ID (1) ID24346A (en)
IL (1) IL133104A0 (en)
NO (1) NO996268D0 (en)
NZ (1) NZ502319A (en)
PL (1) PL337507A1 (en)
SK (1) SK176299A3 (en)
TR (1) TR199903159T2 (en)
WO (1) WO1998058916A1 (en)
ZA (1) ZA985277B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19858779A1 (en) * 1998-12-18 2000-06-21 Basf Ag New 3-acylamino-propionic acid and 3-sulfonylamino-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiovascular and renal disorders, migraine and cancer
DE19924892A1 (en) * 1999-06-01 2000-12-07 Basf Ag New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists
WO2002064573A1 (en) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists
EP1632821B1 (en) 2004-09-01 2012-05-30 Océ-Technologies B.V. Intermediate transfer member with a cleaning member
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8217155B2 (en) 2007-07-31 2012-07-10 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
CN109422664B (en) * 2017-08-23 2022-02-18 中国科学院福建物质结构研究所 Interferon regulator and its prepn and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
DE4411225A1 (en) * 1994-03-31 1995-10-05 Basf Ag Use of carboxylic acid derivatives as a drug
DE19614533A1 (en) * 1996-04-12 1997-10-16 Basf Ag New alpha-hydroxy acid derivatives, their production and use

Also Published As

Publication number Publication date
HUP0002714A3 (en) 2001-07-30
CO4950605A1 (en) 2000-09-01
NO996268L (en) 1999-12-17
WO1998058916A1 (en) 1998-12-30
HRP980331A2 (en) 1999-02-28
ZA985277B (en) 1999-12-20
SK176299A3 (en) 2000-06-12
IL133104A0 (en) 2001-03-19
ID24346A (en) 2000-07-13
DE19726146A1 (en) 1998-12-24
JP2002504130A (en) 2002-02-05
TR199903159T2 (en) 2000-07-21
NO996268D0 (en) 1999-12-17
EP0994861A1 (en) 2000-04-26
BG104022A (en) 2001-04-30
HUP0002714A2 (en) 2001-05-28
PL337507A1 (en) 2000-08-28
CN1261352A (en) 2000-07-26
NZ502319A (en) 2002-03-01
BR9810182A (en) 2000-08-08
KR20010013981A (en) 2001-02-26
CA2294050A1 (en) 1998-12-30
AU8213398A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
MX165708B (en) SALT COMPOSITIONS FOR EXPLOSIVES
PT1140851E (en) 4-OXO-1,4-DIHYDRO-3-QUINOLINACARBOXAMIDES AS ANTIVIRAL AGENTS
PE20020228A1 (en) ORGANIC COMPOUNDS AS INHIBITORS OF 3 ', 5' GUANOSIN CYCLIC MONOPHOSPHATE PHOSPHODIESTERASE
ES2061756T3 (en) PLATINUM COMPLEXES (II), THEIR PREPARATION AND USE AS ANTI-TUMOR AGENTS.
MX167174B (en) SOFTENING DETERGENT COMPOSITIONS
AR015893A1 (en) STRUCTURAL FRAGMENT DERIVED FROM OXYETHYLENE, DERIVATIVES BETA-AMINO AND BETA-AZIDO OF CARBONIC ACID THAT UNDERSTAND IT, ITS USE TO TREAT ASANTAGONIST DISEASES OF ENDOTHELINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS FOR ORGANIZATIONAL COMPREHENSION, WHICH
MY106406A (en) Acryloyl substituted pyrrole derivatives.
ES2095942T3 (en) BENZENOACETAMIDE DERIVATIVES HIV INHIBITORS.
ES2026669T3 (en) PROCEDURE FOR THE PREPARATION AND THERAPEUTIC USE OF BETA-D-PHENYL THIOXYLOSIDES.
CO4980887A1 (en) NEW 3,4-DIARILTIAZOLINA-2-UNO OR 2-TIONO DERIVATIVES, THEIR PREPARATION METHODS AND THERAPEUTIC USE
AR041786A1 (en) DERIVATIVES OF AZETIDINE AS ANTAGONISTS OF THE CCR-3 RECEIVER, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR017418A1 (en) A PUMPABLE AND FLUID WATERY COMPOSITION, USEFUL AS A CONCENTRATED SURFACTING COMPOSITION AND THE PROCESS TO PREPARE IT
AR035242A1 (en) USE OF A HALOGENATED BIOACTIVE LIPID TO PREPARE A CATARTIC COMPOSITION AND HALOGENATED BIOACTIVE LIPID COMPOUND
ES2117132T3 (en) DESFERRIOXAMINE-B SALTS AND THEIR USE AS EFFECTIVE IRON CHELELERS BY ORAL USE.
ES2166098T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 4-OXO-BUTANOIC ACIDS.
GB1229779A (en)
ES2056811T3 (en) CINOLINE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND HERBICIDE COMPOSITIONS THAT CONTAIN THEM.
CO4930270A1 (en) HETERO-CYCLIC DERIVATIVES OF CARBONIC ACID, ITS PRODUCTION AND APPLICATION AS AN ANTAGONISTS OF DEENDOTELIN RECEPTORS
ES2036583T3 (en) IMINOOXAZOLIDINES, PREPARATION PROCEDURE AND METHOD OF USE.
AR247240A1 (en) A useful compound for removing polymeric linings and a method for doing so.
AR017052A1 (en) DERIVATIVES OF CARBOXYL ACID AND ITS USE TO PREPARE MEDICINES.
MX9300008A (en) THERAPEUTIC NUCLEOSIDES.
ES2170537T3 (en) AQUOUS COMPOSITION THAT NEUTRALIZES AMINA FLUORIDE FOR METAL PRE-TREATMENTS CONTAINING AN ORGANIC RESIN AND METAL PRE-TREATMENT PROCEDURE.
PE20010307A1 (en) RUFOMYCIN DERIVATIVES USEFUL AS ANTIBIOTICS
ES2040744T3 (en) A PROCEDURE FOR PREPARING 1,2,4-TRIAZINONE DERIVATIVES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure